{"version":"1.0","type":"link","title":"Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.","author_name":"Tomasini P 외","author_url":"https://prs-insight.online/author/Tomasini%20P","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/96455","thumbnail_width":1200,"thumbnail_height":630}